The European Commission has approved MSD’s Keytruda for use in combination with Eli Lilly’s Alimta and platinum-based chemotherapy for the first-line treatment of some advanced lung cancers.
Read More
MSD’s Keytruda has been awarded full approval in the US in combination with Lilly’s Alimta and platinum chemotherapy as first-line treatment for metastatic non-squamous non-small cell lung cancer.
Read More
US regulators have approved a combination of Eli Lilly’s Alimta and MSD’s Keytruda as first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.
Read More
European regulators have kicked off a review of MSD’s Keytruda/pemetrexed combination for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).
Read More
A combination of MSD’s Keytruda and chemotherapy extended overall survival when used as a first-line treatment of patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
Read More
Eli Lilly has welcomed a decision by the UK Supreme Court that alternative salt forms of its cancer drug Alimta, marketed by Teva’s Actavis, directly infringe on its vitamin regimen patents in the UK, France, Spain and Italy, overturning previous High Court and Court of Appeal judgements.
Read More
The US Food and Drug Administration has issued an accelerated approval for Merck & Co’s immunotherapy Keytruda in combination with pemetrexed (Eli Lilly’s Alimta) and carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.
Read More
The National Institute for Health and Care Excellence has published two sets of guidelines increasing the treatment options for NHS patients with chronic myeloid leukaemia and non-small cell lung cancer.
Read More
NHS use of Eli Lilly’s Alimta to treat patients with lung cancer has been endorsed in final draft guidance from the National Institute for Health and Care Excellence.
Read More
